Exome sequencing reveals frequent deleterious germline variants in cancer susceptibility genes in women with invasive breast cancer undergoing neoadjuvant chemotherapy

Marissa S. Ellingson, Steven Hart, Krishna R Kalari, Vera Jean Suman, Kimberly A. Schahl, Travis J. Dockter, Sara J. Felten, Jason P. Sinnwell, Kevin J. Thompson, Xiaojia Tang, Peter T. Vedell, Poulami Barman, Hugues Sicotte, Jeanette E Eckel-Passow, Donald W Northfelt, Richard J. Gray, Sarah A. McLaughlin, Alvaro Moreno Aspitia, James N. Ingle, Ann MoyerDaniel W Visscher, Katie Jones, Amy Conners, Michelle McDonough, Eric D Wieben, Liewei M Wang, Richard M Weinshilboum, Judy C Boughey, Matthew Philip Goetz

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

When sequencing blood and tumor samples to identify targetable somatic variants for cancer therapy, clinically relevant germline variants may be uncovered. We evaluated the prevalence of deleterious germline variants in cancer susceptibility genes in women with breast cancer referred for neoadjuvant chemotherapy and returned clinically actionable results to patients. Exome sequencing was performed on blood samples from women with invasive breast cancer referred for neoadjuvant chemotherapy. Germline variants within 142 hereditary cancer susceptibility genes were filtered and reviewed for pathogenicity. Return of results was offered to patients with deleterious variants in actionable genes if they were not aware of their result through clinical testing. 124 patients were enrolled (median age 51) with the following subtypes: triple negative (n = 43, 34.7 %), HER2+ (n = 37, 29.8 %), luminal B (n = 31, 25 %), and luminal A (n = 13, 10.5 %). Twenty-eight deleterious variants were identified in 26/124 (21.0 %) patients in the following genes: ATM (n = 3), BLM (n = 1), BRCA1 (n = 4), BRCA2 (n = 8), CHEK2 (n = 2), FANCA (n = 1), FANCI (n = 1), FANCL (n = 1), FANCM (n = 1), FH (n = 1), MLH3 (n = 1), MUTYH (n = 2), PALB2 (n = 1), and WRN (n = 1). 121/124 (97.6 %) patients consented to return of research results. Thirteen (10.5 %) had actionable variants, including four that were returned to patients and led to changes in medical management. Deleterious variants in cancer susceptibility genes are highly prevalent in patients with invasive breast cancer referred for neoadjuvant chemotherapy undergoing exome sequencing. Detection of these variants impacts medical management.

Original languageEnglish (US)
Pages (from-to)435-443
Number of pages9
JournalBreast Cancer Research and Treatment
Volume153
Issue number2
DOIs
StatePublished - Sep 7 2015

Fingerprint

Exome
Neoplasm Genes
Breast Neoplasms
Drug Therapy
Genes
Virulence
Neoplasms
Research

Keywords

  • Breast cancer
  • Exome sequencing
  • Germline mutation/pathogenic germline variant
  • High-risk breast cancer
  • Neoadjuvant chemotherapy
  • Return of results

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Exome sequencing reveals frequent deleterious germline variants in cancer susceptibility genes in women with invasive breast cancer undergoing neoadjuvant chemotherapy. / Ellingson, Marissa S.; Hart, Steven; Kalari, Krishna R; Suman, Vera Jean; Schahl, Kimberly A.; Dockter, Travis J.; Felten, Sara J.; Sinnwell, Jason P.; Thompson, Kevin J.; Tang, Xiaojia; Vedell, Peter T.; Barman, Poulami; Sicotte, Hugues; Eckel-Passow, Jeanette E; Northfelt, Donald W; Gray, Richard J.; McLaughlin, Sarah A.; Moreno Aspitia, Alvaro; Ingle, James N.; Moyer, Ann; Visscher, Daniel W; Jones, Katie; Conners, Amy; McDonough, Michelle; Wieben, Eric D; Wang, Liewei M; Weinshilboum, Richard M; Boughey, Judy C; Goetz, Matthew Philip.

In: Breast Cancer Research and Treatment, Vol. 153, No. 2, 07.09.2015, p. 435-443.

Research output: Contribution to journalArticle

Ellingson, Marissa S. ; Hart, Steven ; Kalari, Krishna R ; Suman, Vera Jean ; Schahl, Kimberly A. ; Dockter, Travis J. ; Felten, Sara J. ; Sinnwell, Jason P. ; Thompson, Kevin J. ; Tang, Xiaojia ; Vedell, Peter T. ; Barman, Poulami ; Sicotte, Hugues ; Eckel-Passow, Jeanette E ; Northfelt, Donald W ; Gray, Richard J. ; McLaughlin, Sarah A. ; Moreno Aspitia, Alvaro ; Ingle, James N. ; Moyer, Ann ; Visscher, Daniel W ; Jones, Katie ; Conners, Amy ; McDonough, Michelle ; Wieben, Eric D ; Wang, Liewei M ; Weinshilboum, Richard M ; Boughey, Judy C ; Goetz, Matthew Philip. / Exome sequencing reveals frequent deleterious germline variants in cancer susceptibility genes in women with invasive breast cancer undergoing neoadjuvant chemotherapy. In: Breast Cancer Research and Treatment. 2015 ; Vol. 153, No. 2. pp. 435-443.
@article{4522523f64c244e0be33b65b8c5ff165,
title = "Exome sequencing reveals frequent deleterious germline variants in cancer susceptibility genes in women with invasive breast cancer undergoing neoadjuvant chemotherapy",
abstract = "When sequencing blood and tumor samples to identify targetable somatic variants for cancer therapy, clinically relevant germline variants may be uncovered. We evaluated the prevalence of deleterious germline variants in cancer susceptibility genes in women with breast cancer referred for neoadjuvant chemotherapy and returned clinically actionable results to patients. Exome sequencing was performed on blood samples from women with invasive breast cancer referred for neoadjuvant chemotherapy. Germline variants within 142 hereditary cancer susceptibility genes were filtered and reviewed for pathogenicity. Return of results was offered to patients with deleterious variants in actionable genes if they were not aware of their result through clinical testing. 124 patients were enrolled (median age 51) with the following subtypes: triple negative (n = 43, 34.7 {\%}), HER2+ (n = 37, 29.8 {\%}), luminal B (n = 31, 25 {\%}), and luminal A (n = 13, 10.5 {\%}). Twenty-eight deleterious variants were identified in 26/124 (21.0 {\%}) patients in the following genes: ATM (n = 3), BLM (n = 1), BRCA1 (n = 4), BRCA2 (n = 8), CHEK2 (n = 2), FANCA (n = 1), FANCI (n = 1), FANCL (n = 1), FANCM (n = 1), FH (n = 1), MLH3 (n = 1), MUTYH (n = 2), PALB2 (n = 1), and WRN (n = 1). 121/124 (97.6 {\%}) patients consented to return of research results. Thirteen (10.5 {\%}) had actionable variants, including four that were returned to patients and led to changes in medical management. Deleterious variants in cancer susceptibility genes are highly prevalent in patients with invasive breast cancer referred for neoadjuvant chemotherapy undergoing exome sequencing. Detection of these variants impacts medical management.",
keywords = "Breast cancer, Exome sequencing, Germline mutation/pathogenic germline variant, High-risk breast cancer, Neoadjuvant chemotherapy, Return of results",
author = "Ellingson, {Marissa S.} and Steven Hart and Kalari, {Krishna R} and Suman, {Vera Jean} and Schahl, {Kimberly A.} and Dockter, {Travis J.} and Felten, {Sara J.} and Sinnwell, {Jason P.} and Thompson, {Kevin J.} and Xiaojia Tang and Vedell, {Peter T.} and Poulami Barman and Hugues Sicotte and Eckel-Passow, {Jeanette E} and Northfelt, {Donald W} and Gray, {Richard J.} and McLaughlin, {Sarah A.} and {Moreno Aspitia}, Alvaro and Ingle, {James N.} and Ann Moyer and Visscher, {Daniel W} and Katie Jones and Amy Conners and Michelle McDonough and Wieben, {Eric D} and Wang, {Liewei M} and Weinshilboum, {Richard M} and Boughey, {Judy C} and Goetz, {Matthew Philip}",
year = "2015",
month = "9",
day = "7",
doi = "10.1007/s10549-015-3545-6",
language = "English (US)",
volume = "153",
pages = "435--443",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",
number = "2",

}

TY - JOUR

T1 - Exome sequencing reveals frequent deleterious germline variants in cancer susceptibility genes in women with invasive breast cancer undergoing neoadjuvant chemotherapy

AU - Ellingson, Marissa S.

AU - Hart, Steven

AU - Kalari, Krishna R

AU - Suman, Vera Jean

AU - Schahl, Kimberly A.

AU - Dockter, Travis J.

AU - Felten, Sara J.

AU - Sinnwell, Jason P.

AU - Thompson, Kevin J.

AU - Tang, Xiaojia

AU - Vedell, Peter T.

AU - Barman, Poulami

AU - Sicotte, Hugues

AU - Eckel-Passow, Jeanette E

AU - Northfelt, Donald W

AU - Gray, Richard J.

AU - McLaughlin, Sarah A.

AU - Moreno Aspitia, Alvaro

AU - Ingle, James N.

AU - Moyer, Ann

AU - Visscher, Daniel W

AU - Jones, Katie

AU - Conners, Amy

AU - McDonough, Michelle

AU - Wieben, Eric D

AU - Wang, Liewei M

AU - Weinshilboum, Richard M

AU - Boughey, Judy C

AU - Goetz, Matthew Philip

PY - 2015/9/7

Y1 - 2015/9/7

N2 - When sequencing blood and tumor samples to identify targetable somatic variants for cancer therapy, clinically relevant germline variants may be uncovered. We evaluated the prevalence of deleterious germline variants in cancer susceptibility genes in women with breast cancer referred for neoadjuvant chemotherapy and returned clinically actionable results to patients. Exome sequencing was performed on blood samples from women with invasive breast cancer referred for neoadjuvant chemotherapy. Germline variants within 142 hereditary cancer susceptibility genes were filtered and reviewed for pathogenicity. Return of results was offered to patients with deleterious variants in actionable genes if they were not aware of their result through clinical testing. 124 patients were enrolled (median age 51) with the following subtypes: triple negative (n = 43, 34.7 %), HER2+ (n = 37, 29.8 %), luminal B (n = 31, 25 %), and luminal A (n = 13, 10.5 %). Twenty-eight deleterious variants were identified in 26/124 (21.0 %) patients in the following genes: ATM (n = 3), BLM (n = 1), BRCA1 (n = 4), BRCA2 (n = 8), CHEK2 (n = 2), FANCA (n = 1), FANCI (n = 1), FANCL (n = 1), FANCM (n = 1), FH (n = 1), MLH3 (n = 1), MUTYH (n = 2), PALB2 (n = 1), and WRN (n = 1). 121/124 (97.6 %) patients consented to return of research results. Thirteen (10.5 %) had actionable variants, including four that were returned to patients and led to changes in medical management. Deleterious variants in cancer susceptibility genes are highly prevalent in patients with invasive breast cancer referred for neoadjuvant chemotherapy undergoing exome sequencing. Detection of these variants impacts medical management.

AB - When sequencing blood and tumor samples to identify targetable somatic variants for cancer therapy, clinically relevant germline variants may be uncovered. We evaluated the prevalence of deleterious germline variants in cancer susceptibility genes in women with breast cancer referred for neoadjuvant chemotherapy and returned clinically actionable results to patients. Exome sequencing was performed on blood samples from women with invasive breast cancer referred for neoadjuvant chemotherapy. Germline variants within 142 hereditary cancer susceptibility genes were filtered and reviewed for pathogenicity. Return of results was offered to patients with deleterious variants in actionable genes if they were not aware of their result through clinical testing. 124 patients were enrolled (median age 51) with the following subtypes: triple negative (n = 43, 34.7 %), HER2+ (n = 37, 29.8 %), luminal B (n = 31, 25 %), and luminal A (n = 13, 10.5 %). Twenty-eight deleterious variants were identified in 26/124 (21.0 %) patients in the following genes: ATM (n = 3), BLM (n = 1), BRCA1 (n = 4), BRCA2 (n = 8), CHEK2 (n = 2), FANCA (n = 1), FANCI (n = 1), FANCL (n = 1), FANCM (n = 1), FH (n = 1), MLH3 (n = 1), MUTYH (n = 2), PALB2 (n = 1), and WRN (n = 1). 121/124 (97.6 %) patients consented to return of research results. Thirteen (10.5 %) had actionable variants, including four that were returned to patients and led to changes in medical management. Deleterious variants in cancer susceptibility genes are highly prevalent in patients with invasive breast cancer referred for neoadjuvant chemotherapy undergoing exome sequencing. Detection of these variants impacts medical management.

KW - Breast cancer

KW - Exome sequencing

KW - Germline mutation/pathogenic germline variant

KW - High-risk breast cancer

KW - Neoadjuvant chemotherapy

KW - Return of results

UR - http://www.scopus.com/inward/record.url?scp=84940960057&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84940960057&partnerID=8YFLogxK

U2 - 10.1007/s10549-015-3545-6

DO - 10.1007/s10549-015-3545-6

M3 - Article

C2 - 26296701

AN - SCOPUS:84940960057

VL - 153

SP - 435

EP - 443

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 2

ER -